These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
418 related items for PubMed ID: 18663448
1. A multiple-center phase II study of biweekly oxaliplatin and tegafur-uracil/leucovorin for chemonaive patients with advanced gastric cancer. Chen JS, Rau KM, Chen YY, Huang JS, Yang TS, Lin YC, Liau CT, Lee KD, Su YC, Kao RH. Cancer Chemother Pharmacol; 2009 Apr; 63(5):819-25. PubMed ID: 18663448 [Abstract] [Full Text] [Related]
2. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma. Jeen YT, Yoon SY, Shin SW, Kim BS, Mok YJ, Kim CS, Hyun JH, Kim JS, Kim YH. Cancer; 2001 Jun 15; 91(12):2288-93. PubMed ID: 11413517 [Abstract] [Full Text] [Related]
3. Phase II study of cisplatin, epirubicin, UFT, and leucovorin (PELUF) as first-line chemotherapy in metastatic gastric cancer. Idelevich E, Karminsky N, Dinerman M, Katsenelson RL, Zvi NB, Baruch NB, Biran H, Man S, Shani A. Acta Oncol; 2007 Jun 15; 46(3):324-9. PubMed ID: 17450467 [Abstract] [Full Text] [Related]
4. Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis. Seo HY, Kim DS, Choi YS, Sung HJ, Park KH, Choi IK, Kim SJ, Oh SC, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS. Cancer Chemother Pharmacol; 2009 Feb 15; 63(3):433-9. PubMed ID: 18398608 [Abstract] [Full Text] [Related]
5. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. Al-Batran SE, Atmaca A, Hegewisch-Becker S, Jaeger D, Hahnfeld S, Rummel MJ, Seipelt G, Rost A, Orth J, Knuth A, Jaeger E. J Clin Oncol; 2004 Feb 15; 22(4):658-63. PubMed ID: 14966088 [Abstract] [Full Text] [Related]
6. Phase I dose escalation study of oxaliplatin combined with oral tegafur-uracil and leucovorin in patients with advanced gastric cancer. Chen JS, Huang JS, Yang TS, Lin YC, Wang HM, Liau CT, Rau KM. Anticancer Drugs; 2005 Jan 15; 16(1):47-51. PubMed ID: 15613903 [Abstract] [Full Text] [Related]
7. A phase II trial of biweekly oxaliplatin with simplified schedule of 48-h infusion of high-dose 5-fluorouracil and leucorvin for advanced biliary tract carcinoma. Chen JS, Chao Y, Yang TS, Chou WC, Chen LT, Lee KD, Lin YC. Cancer Chemother Pharmacol; 2009 Dec 15; 65(1):151-7. PubMed ID: 19455334 [Abstract] [Full Text] [Related]
8. A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer. Oh SY, Kwon HC, Seo BG, Kim SH, Kim JS, Kim HJ. Acta Oncol; 2007 Dec 15; 46(3):336-41. PubMed ID: 17450469 [Abstract] [Full Text] [Related]
9. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer. Jung JY, Kwon JH, Kim JH, Song HH, Kim I, Lee KS, Kim HJ, Zang DY, Ahn JS, Lee JA, Park YI. Oncol Rep; 2009 Feb 15; 21(2):523-9. PubMed ID: 19148531 [Abstract] [Full Text] [Related]
10. Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer. Lin PC, Chen WS, Chao TC, Yang SH, Tiu CM, Liu JH. Cancer Chemother Pharmacol; 2007 Aug 15; 60(3):351-6. PubMed ID: 17111120 [Abstract] [Full Text] [Related]
11. A phase II study of epirubicin, cisplatin and uracil-tegafur for advanced gastric carcinoma. Woo IS, Moon DH, Shim BY, Lee MA, Byun JH, Kim KW, Kang JH, Choi MG, Chung IS, Hong YS, Park SY, Lee KS. Jpn J Clin Oncol; 2005 Jan 15; 35(1):13-7. PubMed ID: 15681598 [Abstract] [Full Text] [Related]
12. Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer. Liu ZF, Guo QS, Zhang XQ, Yang XG, Guan F, Fu Z, Wang MY. Am J Clin Oncol; 2008 Jun 15; 31(3):259-63. PubMed ID: 18525305 [Abstract] [Full Text] [Related]
13. A phase II study of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer. Zhao JG, Qiu F, Xiong JP, Zhang L, Xiang XJ, Yu F, Yan J, Zhan ZY, Feng M. Anticancer Drugs; 2009 Apr 15; 20(4):281-6. PubMed ID: 19247179 [Abstract] [Full Text] [Related]
14. Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer. Cao W, Yang W, Lou G, Jiang J, Geng M, Xi W, Li H, Ma T, Jin Y. Anticancer Drugs; 2009 Apr 15; 20(4):287-93. PubMed ID: 19177020 [Abstract] [Full Text] [Related]
15. Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer. Sym SJ, Hong J, Jung M, Park J, Cho EK, Lee WK, Chung M, Kim HS, Lee JH, Shin DB. Cancer Chemother Pharmacol; 2012 Aug 15; 70(2):277-84. PubMed ID: 22752217 [Abstract] [Full Text] [Related]
16. Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma. Lim JY, Cho JY, Oh KJ, Choi SH, Lee SI, Jeung HC. Chemotherapy; 2009 Aug 15; 55(4):200-6. PubMed ID: 19451710 [Abstract] [Full Text] [Related]
17. Biweekly oxaliplatin, fluorouracil and leucovorin versus cisplatin, fluorouracil and leucovorin in patients with advanced gastric cancer. Popov I, Radosevic-Jelic L, Jezdic S, Milovic M, Borojevic N, Stojanovic S, Stankovic V, Josifovski T, Kezic I. J BUON; 2008 Aug 15; 13(4):505-11. PubMed ID: 19145671 [Abstract] [Full Text] [Related]
18. Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma. Bhandari MS, Pienta KJ, Fardig J, Olson K, Smith DC. Cancer; 2006 Apr 15; 106(8):1715-21. PubMed ID: 16534795 [Abstract] [Full Text] [Related]
19. A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer. Nakajo A, Hokita S, Ishigami S, Miyazono F, Etoh T, Hamanoue M, Maenohara S, Iwashita T, Komatsu H, Satoh K, Aridome K, Morita S, Natsugoe S, Takiuchi H, Nakano S, Maehara Y, Sakamoto J, Aikou T, Kyushu Taxol TS-1 Study Group. Cancer Chemother Pharmacol; 2008 Nov 15; 62(6):1103-9. PubMed ID: 18317763 [Abstract] [Full Text] [Related]